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ABSTRACT: Litigation plague does become a major worry for investors, assignees, 
inventors and related personnels, even holding a quality patent may not secure enough to 
be free from patent litigation.  As long as the patented technology involoved in 
considerable profits, competitors will try every possible measure to take over the market, 
sales order or technology, sometimes aiming to merge or probing core technology, 
moreover for marketing awareness or brand promotion. Accusing patent infringement 
through complicated technical data or wordings, patent invalid through anticipation by 
35 U.S.C. § 102 or obviouness by 35 U.S.C. § 103, or based on details such as priority 
dates, publicizing dates, references, filing dates,…etc. Inequidable conducts are new 
fashions with various tactics like attcking missing lables on embosiments,2 unsupported 
spcification3, obvious to try,4 experiments details,5 chemical structure’s similarity upon 
biological efficacy,6  similarity between dehydrated from and un-dehydrated from,7 
formulation or excipient differences, 8  even a bit late filing information disclosure 
statement (IDS) 9  for new references, crime fraud exception to the attorney-client 
privilege,10 are common tactis in intellectual property disputs. The counteractions will 
be described in details with cases.  
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1.  BACK GROUND 
1.1  Rationale 
In order to take over the market, sales order or technology, filing lawsuits is only to attack the competitors 
but sometimes aiming to merge or probing competitor core technology, moreover, marketing awareness or 
brand promotion can be the purpose for enterprise to against competitors by accusing patent infringement, 
anticipation, using references to invalid patents, obviousness, obvious to try…etc, are using common 
tactics during intellectual property disputs.  However, science & technology does play an important role in 
patent litigation, and those patents were either approved based on advanced, improved or innovative 
findings, therefore, understanding of the foundation for those science and technology are basic preparation 
before going to the courts.  In addition, for those basic attacking tatics, the definitions and legal rationals are 
worth to spend more efforts and study carefully together with those patent related Sciences & Technologies. 
The following are common argued intellectule property issues. 
 
1.2  Infringement  
Infringement either literally or under the doctrine of equivalents is the most common cases in patent 
litigation, however, it is a genuine issue required material fact, the court will request a particularized 
testimony and linking argument to the 『insubstantiality of the differences』 between the claimed invention 
and the accused device or process, or with respect to the function, way, result test to support a finding of 
infringement under the doctrine of equivalents.  The evidence must be presented on a limited-by limited 
basis, however generalized testimony for the overall similarity between the claims and the accused 
infringer’s product or process will not suffice.” 
Infringement under the doctrine of equivalents does not raise a genuine issue of material fact,11 “provide 
particularized testimony and linking argument as to the 『insubstantiality of the differences』between the 
claimed invention and the accused device or process is requested, in addition, the outcome of the function, 
way, result test presented to support a finding of infringement under the doctrine of equivalents is 
acceptable.  Such evidence must be presented on a limited-by limited basis.  Generalized testimony as to the 
overall similarity between the claims and the accused infringer’s product or process will not suffice.” 12 
 
1.3  References  
References are the simplest tools to be applied for attacking competitor’s patent inval.  According to 35 
U.S.C. §10213, a reference14 is defined as the following: 
35 U.S.C. §102 (a) defines the reference as “prior use or knowledge to be considered including the 
invention must be known or used, by others in the United States before the date of the invention”, “prior 
patent or printed publication to be considered including patented or disclosed in a printed publication by 
others anywhere in the World before the date of the invention.  
35 U.S.C. §102 (b) defines the reference as one year period of public knowledge or use or commercial 
exploitation before patent application filed 
35 U.S.C. §102 (e) defines the reference as described in a US patent & published application, or patent 
& publication filed by PCT entering US stage invention by another filed before the date of the applicant’s 
invention PCT published application  
References must be either in the field of the inventor’s endeavor or reasonably pertinent to the specific 
problem with which the inventor was involved, available at the time of the invention.   
                                                 
11 Tex. Instrument Inc. v. Cypress Semiconductor Corp., 90 F.3d 1558, 1567 (Fed. Cir. 1996) 
12 PC connector Solutions LLC v. Smartdisk Corp., 406 F.3d 1359, 1364 (Fed.Cir. 2005) 
13 37 C.F.R. § 1.107 
14 1952 Patent Act for 35 U.S.C. Section 102 
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Reference can also be applied to test for obviousness.  Whether the features of one reference may be 
bodily incorporated into another reference will not decisive, but “whether combined teachings render the 
claimed subject matter obvious”.  
A prior art reference15 is analogous if the reference is in the field of applicant's endeavor or, if not, the 
reference is reasonably pertinent to the particular problem with which the inventor was concerned.16 
A reference may be said to” teach away when a person of ordinary skill, upon reading the reference, 
would be discouraged from following the path set out in the reference, or would be led in a direction 
divergent from the path that the applicant took”. The degree of teaching away depends on the particular 
factors, a reference teaches away if it suggests that the line of development flowing from the reference’s 
disclosure is unlikely to be productive of the result sought by the applicant, the nature of the teaching is 
highly relevant, and must be weighed in substance.17 
A prior art reference that "teaches away" from the claimed invention is a significant factor to be 
considered in determining obviousness. 
 
1.4  Anticipation  
Anticipation is often obscure and hard for people to consider whether the arts are analogous but it is a 
question of fact.  However, there are two criteria relevant in determining whether prior art is analogous:  
(1) Whether the art is from the same field of endeavor, regardless of the problem addressed, and (2) If 
the art is not within the same field of endeavor, whether it is still reasonably pertinent to the particular 
problem to be solved.  
The test for analogous arts is based on the similarity of elements, problems, and purposes.  All 
disclosures of prior art are relevant to the extent if “the references are in analogous fields of endeavor and 
thus have been considered by a person of ordinary skill in the field of invention.”18  In order to claim on 
non-analogous references, based on previous description, we are sure that references must not be within the 
field of the inventor's endeavor, may rely on patentability determinations.  
"Analogous art," by common sense means a person of ordinary skill would reasonably have consulted 
those references and applied their teachings in seeking a solution to the problem that the inventor was 
attempting to solve.19  References, of course, is within the scope of prior art, the “content of the Prior Art” 
and relevant in determining obviousness which is reasonably pertinent to the particular problem with which 
the inventor was involved.20  Analogous prior art has to be the art related to one seeking a solution for 
particular problem, or attempting to achieve a particular result, would look for the purpose of finding the 
answer to that problem, or suggestions as to the attainment of that result.  
The test for analogous art has practiced on the “similarity of elements, problems and purposes."21  
During this type of dispute, the 1952 Patent Act22 does state upon U.S.C. § 10323 : “A patent may not be 
obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, 
if the prior art are such that the subject matter as a whole would have been obvious at the time the invention 
was made to a person having ordinary skill in the art to which said subject matter pertains.  Patentability 
shall not be negative by the manner in which the invention was made.”24 
 
                                                 
15 MPEP Section 2141.01(a) for case law pertaining to analogous art 
16 In re Oetiker, 977 F.2d 1443, 1446, 24 USPQ2d 1443, 1445 (Fed. Cir. 1992) 
17 In re Gurley 31 USPQ2d 1130 (Fed. Cir. 1994) 
18 In re Young, 927 F.2d 588, 591, 18 U.S.P.Q.2d 1089, 1091  (C.A.F.C. 1991) 
19 Heidelberger Druckmaschinen AG v. Hantscho Commercial Prods., 21 F.3d 1068, 1071, 30 U.S.P.Q.2d 1377, 1379 
(C.A.F.C. 1994) 
20 In re Deminski, 796 F.2d 436, 442, 230 U.S.P.Q. 313, 315  (C.A.F.C. 1986) 
21 Plastic Container Corp. v. Continental Plastics of Okla., 515 F. Supp. 834, 214 U.S.P.Q. 530, 541 (W.D. Okla. 1980) 
22 1952 Patent Act for 35 U.S.C. Section 103 
23 American Inventors Protection Act of 1999 (AIPA) (Pub. L. 106-113, 113 Stat. 1501 (1999)) 
24 Intellectual Property and High Technology Technical Amendments Act of 2002 (H.R. 2215) (Pub. L. 107 (2002)) 
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1.5  Obviousness 
In determining obviousness, the invention must be considered “as a whole”, in its entirety rather than 
piecemeal.  The process of determining obviousness has been characterized as not one of merely comparing 
the claims and the accused embodiment detail for details to see if they match, but rather one of examining 
the claimed subject matter as a whole to see if, in light of the prior art, it would have been obvious to one 
skilled in the art.  The “difference” between the prior art and the claimed issue constitutes under 35 U.S.C. 
§ 103. 
The other point to pay attentions is the trend of technology, which provides suggestion or motivation for 
minor changes. A trend might very well constitute a suggestion or teaching to one of ordinary skill in the 
art to make “minor” change from the prior art in accordance with that trend to produce the claimed 
invention.25  The existence of a trend depends on the content of the prior art.  What the prior art would have 
taught one of ordinary skill in the art at the time of this invention?  Evidence cutting against a trend includes 
various different methods used in the prior art to solve the problem faced by the inventor. 
Under 35 U.S.C. §103, teachings of references can be combined only if there is some suggestion or 
incentive to do so while the prior art of record fails to provide any such suggestion or incentive.  Although 
couched in terms of combining teachings found in the prior art, the same inquiry must be carried out in the 
context of a purported obvious "modification" of the prior art.  Unless the prior art suggested the desirability 
of the modification, the mere fact that the prior art may be modified suggested by the examiner does not 
make the modification obvious. 
Obviousness cannot be established by combining the teachings of the prior art to produce the claimed 
invention, absent some teaching, suggestion or incentive supporting the combination.26  It is not allowed to 
use the claimed invention as an instruction manual or “template” to piece together the teachings of the prior 
art so that the claimed invention is rendered obvious.  When consider the obviousness, “one cannot use 
hindsight reconstruction to pick and choose among isolated disclosures in the prior art to deprecate the 
claimed invention”.27   
Failure to provide the necessary suggestion or motivation will create a presumption that the 
combination of references selected by the examiner to support the obviousness rejection was based on 
hindsight. 28 Defining the problem in terms of its solution reveals improper hindsight in the selection of the 
prior art relevant to obviousness.   
 
1.6  Obviousness to try 
What Constitutes “Prior Art” Under 35 USC 103? 
    (1) It must be deemed pertinent or relevant to the claimed subject matter  
    (2) It must be deemed prior in time to the date the claimed invention was made 
“Obvious to try” is not the standard under Section 103 has been directed mainly at two kinds of error.   
In some cases, what would have been “obvious to try” would have been to vary all parameters or try each of 
numerous possible choices until one possibly arrived at a successful result, where the prior art gave either 
no indication of which parameters were critical or no direction as to which of many possible choices is 
likely to be successful.  “Obvious to try” meant to explore a new technology or general approach that 
seemed to be a promising field of experimentation, where the prior art gave only general guidance as to the 
particular form of the claimed invention or how to achieve it."29 
                                                 
25 Monarch Knitting Mach. Corp. v. Sulzer Morat GmbH, 45 USPQ2d 1981.  In re CHU, 36 USPQ2d 1089 (Fed. Cir. 
1995) 
26 In re Geiger 2 USPQ 2d 1276 (Fed. Cir. 1987) 
27 In re Fritch 23 USPQ2d 1780 (Fed. Cir. 1992) 
28 In re Rouffet 47 USPQ2d 1453 (Fed. Cir. 1998) 
29 In re O'Farrell, 853 F.2d 894, 903, 7 USPQ2d 1673, 1681 (Fed. Cir. 1988) 
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"The test for obviousness is not whether the features of a secondary reference may be bodily 
incorporated into the structure of the primary reference, rather than the test is what the combined teachings 
of those references would have suggested to those of ordinary skill in the art." 30   
The totality of the prior art must be considered, and proceeding contrary to accepted wisdom in the art is 
evidence of non-obviousness.31  Furthermore, known disadvantages in old devices which would naturally 
discourage search for new inventions may be taken into account in determining obviousness.32 
 
1.7  Patentability 
A prima facie case of un-patentability is established when the information compels a conclusion that a 
claim is un-patentable under the preponderance of evidence, burden-of-proof standard, giving each term in 
the claim its broadest reasonable construction consistent with the specification, and before any 
consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion 
of patentability.33 
Granting a patent on the discovery of an unknown but inherent function "would remove from the public 
that which is in the public domain by virtue of its inclusion in, or obviousness from, the prior art.34  
“The mere age of the references is not persuasive of the un-obviousness of the combination of their 
teachings, absent evidence that, notwithstanding knowledge of the references, the art tried and failed to 
solve the problem."35  The claimed combination cannot change the principle of operation of the primary 
reference or render the reference inoperable for its intended purpose.36 One cannot show non-obviousness 
by attacking references individually where the rejections are based on combinations of references.37 
Reliance on a large number of references in a rejection does not, without more, weigh against the 
obviousness of the claimed invention.38   
The fact that a combination would not be made by businessmen for economic reasons does not mean 
that a person of ordinary skill in the art would not make the combination because of some technological 
incompatibility.39 
References teach away from the invention or render prior art unsatisfactory for intended purpose.  
However, "the nature of the teaching is highly relevant and must be weighed in substance.   
A known or obvious composition does not become patentable simply because it has been described as 
somewhat inferior to some other product for the same use.40 It is improper to combine references where 
the references teach away from their combination.41  
 
2.  CASES DISCUSSION  
2.1  Aventis Pharma v. Amphastar pharmaceutical & Teva Pharmaceutical42 
This is a very tricky case, as many years later, the inventor was called back to the court to explain the 
complicated science and missing label on comparative experiments.  Finally, due to the missing label and 
titration based comparison for low molecular weight heparins (“LMWHs＂) to find out the best mode.  
Aventis’ expert witness and inventor were considered “intent to deceive”. 
                                                 
30 In re Keller, 642 F.2d 413, 425, 208 USPQ 871, 881 (CCPA 1981) 
31 In re Hedges, 783 F.2d 1038, 228 USPQ 685 (Fed. Cir. 1986) 
32 United States v. Adams, 383 U.S. 39, 52, 148 USPQ 479, 484 (1966). 
33 37 CFR. 1.56(b)(2)(ii) effective as of March 1992 
34 596 F.2d at 1022, 201 USPQ at 661 
35 In re Wright, 569 F.2d 1124, 1127, 193 USPQ 332, 335 (CCPA 1977) 
36 MPEP Section 2143.01 
37 In re Keller, 642 F.2d 413, 208 USPQ 871 (CCPA 1981)  
38 In re Gorman, 933 F.2d 982, 18 USPQ2d 1885 (Fed. Cir. 1991) 
39 In re Farrenkopf, 713 F.2d 714, 219 USPQ 1 (Fed. Cir. 1983) 
40 In re Gurley, 27 F.3d 551, 554, 31 USPQ2d 1130, 1132 (Fed. Cir. 1994) 
41 In re Grasselli, 713 F.2d 731, 743, 218 USPQ 769, 779 (Fed. Cir. 1983) 
42 See supra note 1 
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Missing label in embodiments could happen very often in patents, very minor but extremely important 
details.  But whether it is fair to ignore the profound science in the whole patent but focused on one or two 
missing labels, will it be fair? 
Judge Rader filed dissenting to express his few comments on the decision for “intent to deceive” that (1) 
patent was written by patent agent not the inventor. (2) Highly respected scholar will not risk his reputation 
for hiding one or two label just for the patent. 
Was these 2 missing labels were absent minded mistakes or purposely behaviors?  Writing mistake or 
laboratory mal-management?  Intent to deceive is a state of mind, and it is indeed hard to find the truth.  
Unexpected result not proportion to the chemical structure concentration, it happens, especially for protein 
products, biological effect sometimes can not be rationalized. 
 
2.2  Merck & Co., Inc v Biocraft Laboratories Inc43 
In this case, the main arguments were the Amliloride hydrochloride (K+ conserving) combined with 
hydrochlorothiazide (Na + excreting), both are well known to be diuretic and can be used to treat 
hypertension.  In old days, the concept is Amliloride hydrochloride and hydrochlorothiazide both are 
already known diuretics, therefore, there is no doubt that combination must be more powerful diuretics and 
more effective to treat hypertension.  It seemed “obvious to try”, prima facie obvious. 
Judge Bissell even filed dissenting, a composition must be assessed for obviousness only after 
consideration of its chemical structure as well as its pharmaceutical and biological properties. Hindsight is 
not the standard for determining obviousness. “Obvious to try” which is not barred by 35 U.S.C. § 103. An 
invention is “obvious to try” where the prior art gives either no indication of which parameters are critical 
or no direction as to which of many possible choices is likely to be successful.44  
 
2.3  Apotex Corp. v. Merck& Co45 
Apotex asserted state law claims against Merck for common law fraud and tortious interference with 
prospective economic advantage, and sought to compel discovery pursuant to the crime fraud exception to 
the attorney-client privilege.  During patent litigation, competitor sometimes play games to distract 
attention, or attack just for the purpose of attack.  However, Federal Rule of Civil Procedure 60(b)(3) could 
also be pursuant for the certain strategy, in order to obtain this exception to the privilege, Apotex must make 
a prima facie showing of some foundation for the asserted fraud but in vein.  
"Fraud upon the court should embrace only that species of fraud which does or attempts to subvert the 
integrity of the court itself, or is a fraud perpetuated by officers of the court so that the judicial machinery 
cannot perform in the usual manner its impartial task of adjudging cases that are presented for adjudication", 
fraud upon the court is typically limited to egregious events such as bribery of a judge or juror or improper 
influence exerted on the court, affecting the integrity of the court and its ability to function impartially. 
Apotex’s United States patents No. 5,573,780 (the ‘780 patent) although specified its own process 
involves the detail steps, as set forth in claim 1 of the '780 patent:  
1. A process of manufacture of a pharmaceutical solid composition comprising enalapril sodium, which 
process comprises the steps of:  
(i)(a) mixing enalapril maleate with an alkaline sodium compound and at least one other excipient, 
adding water sufficient to moisten, and mixing to achieve a wet mass, or  
(b) mixing enalapril maleate with at least one excipient other than an alkaline sodium compound, adding 
a solution of alkaline sodium compound in water, sufficient to moisten and mixing to achieve a wet mass;  
                                                 
43 See supra note 3 
44 See supra note 28 
45 See supra note 4 
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thereby to achieve a reaction without converting the enalapril maleate to a clear solution of enalapril 
sodium and maleic acid sodium salt in water;  
(ii) drying the wet mass, and;  
(iii) further processing the dried material into tablets.  
 
However, Merck has market enalapril (the leading ACEI for treating hypertension, heart failure, …etc) 
for years globally, no matter how good this patent coulc be, the timing of filing a patent, publicizied the 
information were the key issues in this case. 
 
2.4  Takeda Chemical Industry v Alphapharm & Genpharm46 
TZD is new type of anti-diabetic medicine which claimed additional benefit on insulin resistance.  
Competitor used Takeda’s own patent to attck Takeda’s patents for obviousness. Whether an invention 
would have been obvious under 35 U.S.C. §103 is a “question of law”, review de novo, based upon 
underlying factual questions which are reviewed for clear error following a bench trial.  If we compare three 
Takeda’s US patents nos: 4,687,777(the ‘777’ patent), 4,287,200(the ‘200’ patent), 4,444,779(the ‘779’ 





















Theafter, the competitors turned the direction to chemistry on the C2H5 substitution.  The argument was 
whether the ethyl subsitution is the skills in the art, luckily, witness suggested that chlorination on Pyridyl 
ring is common but not methylation.  Takeda also proved unexpected result on low toxicity which was the 
key. 
If the differences between the subject matter sought to be patented and the prior art are such that the 
subject matter sought to be patented and the prior art are such that as a whole would have been obvious at 
the time the invention was made to a person having ordinary skill in the art. 35 U.S.C. §103(a), a patent is 
presumed to be valid, 35 U.S.C. §282, the evidentiary burden to show facts supporting a conclusion of 
invalidity, which rests on the accused infringer, is one of clear and convincing evidence.  
                                                 
46 See supra note 5 
強調血脂肪及血糖控制效果 
強調抗糖尿病用藥 
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Blood sugar control effect 
Blood sugar & Lipid control effect 
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2.5  Tap Pharmaceutical & Takeda  Chemical Industry & Wako Pure Chemical 
Industries & Abbott Laboratories v OWL Pharmaceuticals & Oakwood 
Laboratories47 
Product in suit was a 9 amino acids sequence, more potent than nature version. Takeda sucessfully recevied 
five indications arrpoved from FDA on Prostate cancer, Endometriosis (suggested 6 months treatment), 
uterine myoma (suggested  3 months treatment), central precocious puberty (CPP), Pre-menopause breast 
cancer. Takeda also developed 1 month depot vial, 3 months depot vial, 6 months depot vial, vial plused 
syringe, formulation without gelatin forms with patents respectively.  
However, competitors attacked on the differntiation for reaction adding dehydrated form (glycolide or 
lactide) and un-dehydrated form (glycolic acid or lactic acid), Takeda was too conservative during the claim 
construction which led to too narrow explaination.  Competitor tried to rule out one selection, then leave 
themselves the room for business.   
For scientist, both dehydrated form (glycolide or lactide) or un-dehydrated from (glycolic acid or lactic 
acid) can be used for reactions with minor adjustment as it should be conisder as the skills in the art.  
However, for people in law profession do not see things in this way, it would be totally different stuffs for 
them as the different structures with different names.  Again, it would be more tricky for scientist to answer 
whether they are the same or they are different.   In fact, dehydrated form of glycolide or lactide are not 
quite the same as the un-dehydrated from of glycolic acid or lactic acid, but they are also not so different.  
But in the court, during the deposition, if you were the scientist, shall you answer they are the same or they 
are different? Turly tough. 
The other important issue in this case is proper language in patent writing, never use 【containing ] in 
the claim which could be attacked as non-professional writing.  In Takeda’s US patent no: 5476663 ( the 
“663 patent): Claim 1  
【A prolong release microcapsule for injection, which comprises particles containing a water-soluble 
drug, the particle being dispersed in a spherical microcapsule matrix composed of a copolymer of lactic 
acid and glycolic acid having a comonomer ratio within the range of about 100/0 to 50/50 and an average 
molecular weight within the ranged of about 5000 to 200,000, the spherical microcapsule matrix having an 
average diameter of 2 to 200 um and an excipient selected from the group consisting of mannitol, sorbital, 
lactose and glucose, which particles are produced by in-water drying. ] 
With profound scientific evidences and conservative characters, Takeda managed to succed in the past 
litigations.  However, this time, Takeda was attacked on inequitable conduct, simply because 2 papers 
added information disclosure statement (IDS), competitors could exaggerate that Takeda purposely delay 
submitting important information, intent to deceive, in case the negative approval decision by examinor.  
Although, those two paper was considered to be non-inflential for the decision of patent approval but the 
time consuming, litigation expanses increase, tension and pressure for the stock price…etc, the cost is huge. 
 
2.6  In re Omeprazole, AstraZeneca v Andrx pharmaceutical & Genpharm48 
AstraZeneca is one of the leading pharmaceutical company in the world, Omeprazol generated billions 
revenus to the company for years, with new slow release form, this new version of omeprazole continuely 
its services to contribute tons of cash into AztraZeneca with more than five indications on Duodenal ulcer, 
Gastric ulcer: short term treatment, Treatment of gastroesophageal reflux disease (GERD), Maintenance of 
healing of erosive esophagitis and Phtologcal hypersecretory conditions.  Not only performed the legendary 
litigation role model in intellectual property, AstraZeneca also made a brilliant track records on 
medical/clinical trials and marketing planning. 
                                                 
47 See supra note 6 
48 See supra note 7 
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Till date, there were more than three waves litigation ongoing for generic companies, most of generic 
companies either tried to change coating polyers or excipients, however, when consider the primary 
concern for the invention, if the key ingredient remain the same, without major process/ manufacture 
improvement or new formulation, it is hard to survive when confronting the top tier attorneies hired by 
AstraZeneca.  Let us compared the Astrazeneca’s US patent no 4,853,230 ( the ‘230 Patent) and 
4,786,505( the ‘505 Patent) with the patents from generic companies:  
Claim 1 of Astrazeneca’s ‘230 patent 
 An pharmaceutical preparation comprising 
(a) a alkaline reacting core comprising an acid-labie pharmaceutical active substance and an 
alkaline reacting compound different from said active substance, an alkaline salt of an acid-labile 
pharmaceutical active substance, an alkaline salt of an acid-pharmaceutically active substance and an 
alkaline reacting compound different from said active substance;  
(b) An inert subcoating which rapidly dissolves or disintegrates in water disposed on said core 
region, said subcoating comprising one or more layers of materials selected from among tablet excipients 
and polymeric film-forming compounds and alkaline compounds; and 
(c) an enteric coating layer surrounding said subcoating layer, wherein the subcoating layer isolates the 
alkaline reacting core from the enteric layer that the stability of the preparation is enhanced. 
(2) Genpharm’s formulation: 
a sugar core; 
an active drug layer (containing micronized omeprazole) sprayed onto the sugar core; 
a protective coating layer of HMPC (hydroxypropyl methy;cellulose) sprayed onto the active drug 
layer; and 
an enteric coating sprayed onto  the protective coating 
(3) Cheminor’ s formulation: 
a  core pellet (containing omeprazole and meglumine [N-methylglucamine], an alkaline compound); 
a  coating made of polyvinylpyrrolidone (｀PVP＂); 
an enteric coating (made of eudragit L100-55, triethyl citrate and magnesium stearate). 
(4) Andrx’ s formulation: 
a  sugar core; 
a  homogenized suspension of micronized omeprazole, sodium laury sulphate (dispersant), disodium 
hydrogen phosphate (stablizer), lactose (filler)m providone (binder), and water, sprayed onto the 
core; 
A homogenized enteric coating containing hydroxypropyl methylcellulose phthate (“HPMCP”), 
acetyl alcohol, talc, acetone, and isopropyl alcohol. 
 
(5) KUDCo’s formulation: 
(a)  a microtablet core (containing omeprazole, HMPC, and lactose particles); 
(b) a subcoat (same as that of the｀505 and｀230 patents); and 
(c) an enteric coat (same as that of the｀505 and｀230 patent) 
 
(6) Claim 1 of Astrazeneca’s ‘505 patent 
An oral pharmaceutical preparation comprising 
(a) a core region comprising an effective amount of a material selected from the group consisting of 
omeprazole plus an alkaline reacting compound, an alkaline omeprazole salt plus an alkaline 
reacting compound and an alkaline omeprazole salt alone 
(b) An inert subcoating which is soluble or rapidly disintegrating in water disposed on said core 
region, said subcoating comprising one or more layers of material selected from among tablet 
excipients and polymeric film-forming compounds, and 
(c) an outer layer disposed on said subcoating comprising an enteric coating  
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Only KUDCo was not infringed both ‘230 and ‘505 patents, therefore, small change of formulation or 
excipients although made the wording difference, however, if the nature of the technology (using polymer 
for coating the capsule) was not improved with differntiable advancement, the patentability will be 
challenged if the profits are considerably attracktive..  
 
3.  CONCLUSION 
3.1  How to overcome Obviousness 
In order to overcome the obviousness, evidence from some of ordinary skill were skeptical of the 
advantages of the invention may show “unexpected result”.  General skepticism of those in the related art 
not only amounting to teaching away but also “relevant and persuasive evidence” of non-obviousness.49  An 
inventor has probed the strengths and weakness of the prior art and discovered an improvement that 
escaped those who came before is indicative of not obviousness.50   
It is not sufficient to establish obviousness that the separate elements of the invention existed in the prior 
art, absent some teaching or suggestion, in the prior art, to combine the elements.51  The evidence that the 
combination was not viewed as technically feasible must be considered, for conventional wisdom that a 
combination should not be made is evidence of non-obviousness.   The motivation in the prior art to 
combine the references does not have to be identical to that of the application to establish obviousness.52 
It is not required to support an obviousness rejection if a prior art reference explicitly contain all the 
necessary features of the claimed invention.  The key is the “inherent teaching of a prior art reference can be 
used to overcome an obviousness rejections”53   
 
3.2  How to overcome anticipation 
There are few suggestions for overcome anticipations as listed below: 
A factor cutting against a finding of motivation to combine or modify the prior art is when the prior art 
teaches away from the claimed invention.  
A person of ordinary skills, upon reading the reference, would be discouraged from following the path 
set out in the reference, unexpected results are often applied tactics. 
Applicants may argue that the examiner's conclusion of obviousness is based on improper hindsight 
reasoning. However, "any judgement on obviousness is a sense necessarily a reconstruction based on 
hindsight reasoning, but so long as it takes into account only knowledge which was within the level of 
ordinary skill in the art at the time the claimed invention was made and does not include knowledge gleaned 
only from applicant's disclosure, such a reconstruction is proper."54 
As discussed in Manual of Patent Examination Procedure(MPEP) Section 2143.01 there must be some 
suggestion or motivation, either in the references themselves or in the knowledge generally available to one 
of ordinary skill in the art, to modify or combine reference teachings.  The federal circuit has produced a 
number of decisions overturning obviousness rejections due to lacking of suggestion in the prior art of the 
desirability in combining references.  In addition to the material in MPEP Section 2141.02, prior art must be 
considered in its entirety, including disclosures that teach away from the claims and MPEP Section 2143.01 
proposed modification cannot render the prior art unsatisfactory for its intended purpose or change the 
principle of operation of a reference.   
 
                                                 
49 Gillette Co. v. S.C. Johnson & Son 16 USPQ2d 1923 (Fed. Cir. 1990) 
50 Fromson v. Anitec Printing Plates, inc. (Fed. Cir. 1997) 
51 Arkie Lures, Inc. v. Gene Larew Tackle, Inc. 43 USPQ2d 1294 (Fed. Cir. 1997) 
52 In re Kemps, 40 USPQ2d 1309 (Fed. Cir. 1996)  
53 In re Grasselli, 218 USPQ 769 (Fed. 1983) 
54 In re McLaughlin 443 F.2d 1392, 1395, 170 USPQ 209, 212 (CCPA 1971). 
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3.3  What is the most important lessons after all: 
Upon the previous cases, in order to defense the infringement, obviousness or anticipation, the following 
legal countermeasures experiences are recommended: 
(1)The literal infringment must be prevented before submission, it is unforgiveable to be found the 
exactly the same figures or description in the prior art belonged to the applicant.   
(2) Applicant’s FTP (file transfer protocol) and website will also be considered as proper public 
communication case by case.   
(3)Filing date and publicity date are crucial details required extra attentions even during the paper 
submission through internet/e-mail.  
(4) Laboratory managemnt shall be carefully maintained and monitors for all data and writing. 
(5) Carefully communication with patent agent throughout the whole patetn writing process  
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